Zepbound Results Timeline: What the Trials Show Week by Week
A week-by-week walk through what happened to trial participants on tirzepatide — from the first low dose through escalation, the steep middle stretch, the plateau, and what the three-year data shows.
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.
People searching for a Zepbound timeline usually want one of two things: reassurance that what is happening to them is normal, or a sense of what comes next. Clinical trials can help with both — but only as a description of what happened to groups of people, not as a forecast for any individual.
Everything below comes from published tirzepatide trials. Nothing here is a recommendation about dose or about whether to take the drug. Those are conversations for a healthcare provider.
One structural point first, because it explains the whole shape of the timeline: the trials did not start people at the dose they finished on. In SURMOUNT-1, everyone began at 2.5 mg weekly and increased by 2.5 mg every four weeks. Reaching the 5 mg maintenance dose took four weeks. Reaching 10 mg took twelve. Reaching 15 mg took twenty [1][2]. So a participant assigned to 15 mg spent nearly five months climbing before they were on their full dose.
Weeks 1 to 4: what does the starting dose actually do?
This is the 2.5 mg stretch, and in the trials it was explicitly a starting step rather than a treatment dose.
Weight curves in SURMOUNT-1 began separating from placebo early, but the separation in the first month was modest. What participants reported most in this window was gastrointestinal — nausea, reduced appetite, constipation, diarrhea. Across the tirzepatide program, these events were most common during escalation and tended to ease afterward [1].
The SURMOUNT-1 protocol also built in flexibility for people struggling: doses could be temporarily interrupted for one week, and participants at higher steps could be moved back down a level if symptoms persisted [2]. That is a design detail, not a suggestion — any change to a prescription is a clinical decision.
Weeks 5 to 12: when do the first thresholds get crossed?
By week twelve, a participant assigned to 5 mg had been at their target dose for two months. A participant assigned to 10 mg had just reached theirs. A participant assigned to 15 mg was still climbing.
Week 12 matters because trials use it as a checkpoint. In a SURMOUNT-1 analysis of 1,545 participants who took at least 75% of their assigned doses [3]:
- 1,267 participants (82%) had lost 5% or more of body weight by week 12. Researchers called these early responders.
- 278 participants (18%) had lost under 5%. These were the late responders.
Late responders were not a random subset. They were more likely to be male (45% versus 30%) and started heavier — 110.2 kg versus 103.6 kg, with a higher BMI and larger waist.
Weeks 13 to 24: does a slow start mean it will not work?
This is the single most useful finding in the tirzepatide timeline literature, and it argues against writing off a slow start.
By week 24 — four weeks after the end of dose escalation — 194 of the 278 late responders (70%) had reached 5% or more weight loss. By week 72, that number was 250 out of 278, or 90% [3].
Among late responders who eventually got there, the average time to reach 5% was 24.8 weeks, with a standard deviation of 12.7 weeks. That is roughly six months, with wide variation.
The catch is that slow starters did not catch up all the way. At week 72, the late-responder group averaged 11.0% total weight loss (-12.0 kg), while early responders averaged 22.5% (-23.2 kg). Within the late-responder group, the final figures split by dose: 8.3% at 5 mg, 11.4% at 10 mg, 13.6% at 15 mg.
So: a slow first three months predicted a smaller final result on average, but it did not predict failure. That is a trial observation. Anyone whose response looks slower than expected should raise it with their prescriber rather than draw conclusions from a group average.
Weeks 25 to 40: what does the steep stretch look like?
By week 20, everyone in SURMOUNT-1 was at their assigned maintenance dose. This is the stretch where the trial curves are steepest and where the doses pull apart from each other most visibly.
It is also where the plateau analysis says most people were still actively losing. That analysis, pooling 1,438 adherent SURMOUNT-1 participants and 259 from SURMOUNT-4, defined a plateau as less than 5% weight change across a 12-week interval and every interval after it. Median time to plateau by starting BMI category [4]:
| Starting category | Median time to plateau |
|---|---|
| Overweight | 24.3 weeks |
| Class I obesity | 26.0 weeks |
| Class II obesity | 36.1 weeks |
| Class III obesity | 36.1 weeks |
The differences for class II and class III versus overweight were statistically significant (p<0.05). Three other factors pushed the plateau later: higher tirzepatide doses (10 mg or 15 mg), younger age, and female sex.
Read that table carefully. A median of 24 to 36 weeks means half the group had plateaued by then and half had not. It is a midpoint, not a deadline.
Weeks 41 to 72: when does it level off?
By week 72 — the primary endpoint for SURMOUNT-1, SURMOUNT-2, SURMOUNT-3 and SURMOUNT-5 — between 87.6% and 90.2% of SURMOUNT-1 participants had reached a plateau across all BMI categories [4].
The 72-week averages for SURMOUNT-1 [1]:
| Dose | Mean weight change at week 72 |
|---|---|
| 5 mg | -15.0% |
| 10 mg | -19.5% |
| 15 mg | -20.9% |
| Placebo | -3.1% |
And the threshold rates: 85% to 91% of tirzepatide participants lost at least 5%, while 50% of the 10 mg group and 57% of the 15 mg group lost at least 20%.
A plateau in this sense does not mean nothing more happens. It means the rate of change has slowed below a defined threshold. In SURMOUNT-MAINTAIN, participants continued open-label treatment for a full 60 weeks before randomization, and the design specifically screened for people whose weight had changed less than 5% between weeks 48 and 60 — a formal acknowledgment that by roughly a year in, most people have settled [5].
What happens in year two and year three?
The longest randomized tirzepatide data comes from the SURMOUNT-1 prediabetes extension, which kept 1,032 participants on treatment for 176 weeks and then followed them for 17 weeks off treatment [6].
| Dose | Week 72 | Week 176 |
|---|---|---|
| 5 mg | -15.0% | -12.3% |
| 10 mg | -19.5% | -18.7% |
| 15 mg | -20.9% | -19.7% |
| Placebo | -3.1% | -1.3% |
The group held close to its peak for another two years. It did not keep dropping, and it did not collapse.
That extension also delivered the most striking long-term finding in the program: over 176 weeks, 1.3% of the tirzepatide participants developed type 2 diabetes versus 13.3% on placebo (hazard ratio 0.07; 95% CI 0.0 to 0.1). After 17 weeks off treatment, the gap narrowed but held: 2.4% versus 13.7% [6].
SURMOUNT-MAINTAIN gives a second view of the second year, this time with absolute weights. Participants entered at an average of 112 to 113 kg, came down to about 89 kg over 60 weeks, and then a year later stood at 88.7 kg if they stayed on their maximum tolerated dose, or 94.6 kg if they dropped to 5 mg [5].
What happens on the timeline if treatment stops?
It reverses, and faster than it accumulated.
In SURMOUNT-4, 670 participants spent 36 open-label weeks on tirzepatide, losing an average of 20.9%. They were then randomized either to keep going or to switch to placebo. Over the next 52 weeks, the continued group lost a further 5.5%. The placebo group gained 14.0% — a 19.4-percentage-point gap. By week 88, 89.5% of the continued group had kept at least 80% of their lead-in loss, versus 16.6% of the placebo group [7].
SURMOUNT-MAINTAIN adds a middle option. Participants who stepped down to 5 mg instead of stopping outright ended the year at -16.6% from baseline, against -21.9% for those who stayed on the full dose and -9.9% for placebo [5]. Rescue treatment for major regain was needed by 8% of the full-dose group, 25% of the 5 mg group and 67% of the placebo group.
Does the real-world timeline look the same?
Not quite. In a US electronic health record study of 1,003 tirzepatide patients with obesity and no diabetes who stayed on treatment, average weight loss at six months was 11.15% [8].
Compare that with the trial curves, where six months lands somewhere in the steep middle stretch. The real-world figure is lower, and the likely reasons are structural: only 42.4% of those patients had reached 10 mg or higher, and they did not have the dietitian counseling, free medication and frequent visits that trial participants had.
That study also only included people still taking the drug at six months. Persistence data from a separate US claims analysis of 33,607 people found about 65% of tirzepatide starters were still on treatment at one year [9] — better than semaglutide in the same dataset, but well short of the 90%-plus completion rates seen in the trials.
The short version
- Weeks 1-4. Starting dose. Side effects are most common here.
- Weeks 5-20. Stepwise escalation. About 82% of adherent trial participants had lost 5% or more by week 12.
- Weeks 13-24. Most slow starters catch the 5% mark. Average time to 5% among them was about 25 weeks.
- Weeks 20-40. Full dose, steepest part of the curve. Median plateau lands between 24 and 36 weeks depending on starting BMI.
- Week 72. Roughly 88-90% have plateaued. Group averages: 15.0%, 19.5%, 20.9% by dose.
- Weeks 72-176. Weight holds close to peak on continued treatment.
- After stopping. Regain averaged 14.0% over 52 weeks in SURMOUNT-4.
Every one of these is a group average from a trial with structured support. Your own timeline is a question for your healthcare provider, not for a chart.
Sources
- SURMOUNT-1, New England Journal of Medicine 2022 — https://pubmed.ncbi.nlm.nih.gov/35658024/
- Zepbound NDA 217806 statistical review, FDA — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217806Orig1s000StatR.pdf
- SURMOUNT-1 early versus late responder analysis, Diabetes Obesity and Metabolism 2025 — https://pubmed.ncbi.nlm.nih.gov/40677091/
- Time to weight plateau in SURMOUNT-1 and SURMOUNT-4, Clinical Obesity 2025 — https://pubmed.ncbi.nlm.nih.gov/39800653/
- SURMOUNT-MAINTAIN, The Lancet 2026 — https://pubmed.ncbi.nlm.nih.gov/42119587/
- SURMOUNT-1 three-year prediabetes analysis, New England Journal of Medicine 2025 — https://pubmed.ncbi.nlm.nih.gov/39536238/
- SURMOUNT-4, JAMA 2024 — https://pubmed.ncbi.nlm.nih.gov/38078870/
- Truveta comparative effectiveness cohort, Journal of Endocrinological Investigation 2026 — https://pubmed.ncbi.nlm.nih.gov/41661445/
- GLP-1 persistence trends, Journal of Managed Care & Specialty Pharmacy 2026 — https://pubmed.ncbi.nlm.nih.gov/41760566/
Questions people ask
How soon does Zepbound start working?
In SURMOUNT-1, the tirzepatide groups separated from placebo within the first few weeks, while everyone was still on the 2.5 mg starting dose. But the meaningful thresholds came later. Among participants who reached at least 5% weight loss, the average time to get there was measured in months, not weeks.
What is a normal amount of weight loss at 12 weeks on Zepbound?
Trials use 5% at week 12 as the dividing line. In a SURMOUNT-1 analysis of 1,545 adherent participants, 82% had lost at least 5% by week 12 and 18% had not. Both groups kept losing after that.
Is Zepbound not working if I have lost nothing after 3 months?
Not necessarily. Of the 18% of SURMOUNT-1 participants who had lost under 5% at week 12, 70% reached 5% by week 24 and 90% reached it by week 72. Their average total loss at 72 weeks was 11.0%, about half that of early responders. This is a trial observation, not advice — discuss a slow response with a healthcare provider.
When does weight loss plateau on tirzepatide?
An analysis of SURMOUNT-1 and SURMOUNT-4 defined a plateau as under 5% weight change over a 12-week stretch and every stretch after. The median time to plateau ranged from 24.3 weeks in participants with overweight to 36.1 weeks in class III obesity. By week 72, 88% to 90% had plateaued.
Why does it take 20 weeks to reach the top dose?
Because that is how the trials were designed. Participants started at 2.5 mg and increased by 2.5 mg every four weeks. Reaching 5 mg took 4 weeks, 10 mg took 12 weeks and 15 mg took 20 weeks. The FDA-approved labeling follows the same stepwise structure.
Does weight loss keep going after a year?
It slows. At 72 weeks the 15 mg group averaged 20.9%. At 176 weeks, in the prediabetes extension, the same dose averaged 19.7%. The group essentially held its loss for another two years rather than continuing to lose.
Do men and women follow different timelines?
In the plateau analysis, women and younger participants tended to reach a plateau later, meaning they kept losing for longer. Participants starting at a higher BMI also plateaued later.
What happens in the weeks after someone stops?
In SURMOUNT-4, participants switched to placebo after 36 weeks regained an average of 14.0% of body weight over the following 52 weeks, while those who stayed on the drug lost a further 5.5%.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.